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Abstract
High cytomegalovirus (CMV) IgG levels have been identiﬁed as a
risk factor for arteriovenous ﬁstula (AVF) failure. None of the
68 patents in our study were CMV IgM positive, although 96%
were CMV IgG positive. CMV antigens were detected in the
radial artery or cephalic vein of 46% of patients who received an
AVF. The presence of CMV antigens or high serum CMV IgG
levels had no prognostic value for AVF failure.
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Cytomegalovirus (CMV), a member of the herpesviridae fam-
ily, establishes latency after primary infection, is reactivated
by inﬂammation and can sustain an inﬂammatory response
[1]. Based on its pro-inﬂammatory properties, CMV is
believed to mediate the development of various vascular dis-
eases [1,2]. CMV has been detected in abdominal aortic
aneurysm [3,4], atherosclerosis and transplant vascular scle-
rosis [2,5]. High anti-CMV IgG levels also have predictive
value for coronary heart disease [6], and for all-cause and
cardiovascular mortality [7,8]. Noteworthy is that several
studies have been unable to conﬁrm the presence and poten-
tial role of CMV in these conditions [5,9–12].
Native arteriovenous ﬁstula (AVF) is the preferred form of
haemodialysis access but because of dysfunction it also
remains a major cause of morbidity in these patients [13]. Fail-
ure of AVF is predominantly the result of venous stenosis and
thrombosis; AVF patency rates at 2 years after construction
are approximately 75%, when ﬁstulae that fail to mature ade-
quately to support haemodialysis are excluded [14]. Although
numerous risk factors for AVF failure have been identiﬁed,
they do not explain all the AVF failures [15]. High anti-CMV
IgG levels have been identiﬁed as an independent risk factor
for haemodialysis access thrombosis [16,17]. We examined
the CMV IgG and IgM levels, and the presence of CMV pro-
teins in the vessels and their effects on AVF outcome.
In this prospective study, 68 patients with end-stage renal
disease who received a native haemodialysis AVF at the
Department of General, Vascular and Oncologic Surgery,
Central Clinical Hospital Ministry of Internal Affairs, Warsaw,
Poland, between 1 June 2006 and 30 September 2007 were
included. The patients were aged 62 ± 15 (mean ± SD) years
at the time of surgery, and 46 (68%) were men. They were
followed for 24 months or until AVF failure, the study end-
point. Informed consent was obtained from all patients, and
the ethical committees at Karolinska Institutet (2011/411-31/
1) and at the Central Clinical Hospital Ministry of Internal
Affairs (40/2005) approved the study. The AVF failure rate at
24 months was 50% in this population, of which 15% was as
a result of primary failure, consistent with previous observa-
tions [18].
The CMV serological status (IgG and IgM) of the patients
was determined before surgery using an automated analyser
and the Liaison CMV IgG and IgM assays (DiaSorin, Saluggia,
Italy). All patients were CMV IgM negative, whereas 65
(96%) were CMV IgG positive, with titres ranging between
1.7 and >22 IU/mL. Three patients (4%) were CMV IgG neg-
ative (levels <0.2 IU/mL), and their ﬁstulae functioned for 3–
6 months after surgery. The patient population was divided
into tertiles for subsequent analysis, based on serum CMV
IgG levels (ﬁrst tertile: <0.2 to 9.2 IU/mL, second tertile:
>9.2 to 17.0 IU/mL and third tertile: >17 to >22 IU/mL).
Patency rates of the AVF were analysed using Kaplan–Meier
curves and evaluated by log-rank test. Higher CMV IgG titres
were not associated with lower durations of AVF function
(p = 0.52) (Fig. 1).
The radial artery and cephalic vein biopsies that were
obtained at the surgical creation of AVF were stained for
CMV immediate early (IEA) and late (LA) antigens by immu-
nohistochemistry as described previously [3]. Brieﬂy, follow-
ing deparafﬁnization and blocking, sections were stained with
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antibodies against CMV IEA and LA (both from Chemicon
International, Temecula, CA, USA), and alpha smooth muscle
actin (BioGenex, San Ramon, CA, USA), which was used as a
control; followed by staining with a secondary biotinylated
antibody and streptavidin-conjugated horseradish peroxidase
(both from BioGenex). The antigens were visualized using
the chromogen diaminobenzidine (Innovex Biosciences, Rich-
mond, CA, USA).
The CMV IEA/LA were detected in the radial arteries of
38% of patients evaluated but were present in only 19% of
the cephalic veins evaluated. In the majority of biopsies, a
few scattered CMV-positive cells were observed, and the
CMV proteins were expressed predominantly in inﬂamma-
tory cells (Fig. 2a,b). To determine the potential prognostic
value of the presence of CMV proteins in the vessels, Kap-
lan–Meier curves were constructed for the patients with
and without CMV vessel antigens. The curves were com-
pared using the log-rank test. No signiﬁcant difference in
AVF failure rate was noted between the groups (p = 0.85)
(Fig. 2c).
High CMV IgG serum levels, which have been associated
with AVF failure in two studies, had no predictive value for
AVF failure in our study. In the retrospective case–control
study by Grandaliano et al. [16], a deﬁned cut-off that corre-
sponded to approximately the top 17% of CMV IgG popula-
tion levels was used, versus the cut-off set corresponding to
approximately the top 13% of CMV IgG population levels used
by Gagliardi et al. [17]. Further, CMV serology was not evalu-
ated before AVF construction in these studies, and neither
study examined the presence of CMV in the affected vessels.
Solely serological approaches are problematic, because
CMV antibody titres can ﬂuctuate tremendously through
repeated reactivation of latent infections. Any association
between AVF failure and CMV IgG levels measured at a spe-
ciﬁc time-point will be substantially weaker than associations
of AVF failure with average CMV IgG levels over longer peri-
ods or with the presence of CMV at the anatomically rele-
vant site [5].
Notably, although we detected CMV proteins in the ves-
sels of 46% of the patients at the time of surgery, the pres-
ence of CMV proteins was not predictive of AVF failure.
Our results do not fully exclude CMV as a potential contrib-
utor to AVF failure, and it is possible that CMV activity is
triggered at a later stage, potentially contributing to AVF fail-
ure. Further prospective studies that evaluate consecutive
serum samples for CMV IgG and examine vessels at the time
FIG. 1. No signiﬁcant differences were observed in arteriovenous
ﬁstula (AVF) patency rates in patients with high cytomegalovirus
(CMV) IgG levels. First tertile: <0.2 to 9.2 IU/mL, second tertile:
>9.2 to 17.0 IU/mL and third tertile: >17 to >22 IU/mL.
(a)
(c)
(b)
FIG. 2. Cytomegalovirus (CMV) protein-posi-
tive cells (brown) were found in the radial
arteries of 38% of the patients evaluated while
they were present in only 19% of the cephalic
veins of the patients evaluated (IEA, immediate
early antigen) (a). Alpha smooth muscle actin
(a-SMA) was used as a positive control (b).
Presence of CMV antigens in the vessels does
not have prognostic value for arteriovenous
ﬁstula (AVF) patency (c).
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of construction and failure are warranted to fully address the
potential role of CMV in AVF failure.
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